智翔金泰：公司“抗体产业化基地项目二期”已完成主体建筑封顶，计划于2030年正式投产

Core Viewpoint - The company has adjusted its fundraising plans, reducing capacity investment, which raises questions about the expected sales of its current and upcoming products [2]. Group 1: Production Capacity - The company has established a production capacity of 24,400 liters for antibody raw materials, which is sufficient to meet the commercial production needs for products like the Celerion monoclonal injection and the Slevem monoclonal injection before 2030 [2]. - The company is optimizing its production schedule and enhancing production processes to ensure that current capacity meets the clinical production needs of other products under development [2]. Group 2: Future Expansion - The second phase of the company's antibody industrialization base project has completed the main building's topping-out and is scheduled to commence production in 2030, which will further expand the company's antibody raw material production capacity [2]. - The adjustments in fundraising and the addition of new sub-projects are based on the company's actual research and operational needs, which will facilitate the smooth implementation of related research and operations and improve the efficiency of fundraising utilization [2].